Monopar Therapeutics Inc.

NasdaqCM:MNPR Stock Report

Market Cap: US$637.9m

Monopar Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

NasdaqCM:MNPR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
26 Dec 25BuyUS$104,925Quan VuIndividual1,500US$69.95
18 Dec 25SellUS$343,889Arthur KlausnerIndividual5,121US$68.09
24 Sep 25SellUS$34,999,957Tactic Pharma LLCCompany550,229US$63.61

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of MNPR?
Owner TypeNumber of SharesOwnership Percentage
Hedge Funds345,6264.42%
Individual Insiders478,4446.12%
Public Companies522,6676.69%
Private Companies567,5807.26%
VC/PE Firms667,2078.54%
Institutions5,231,09067%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 102.26% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
19.7%
Janus Henderson Group Ltd.
1,317,410US$125.4m0%0.04%
9.96%
RA Capital Management, L.P.
667,207US$63.5m0%0.67%
8.47%
Tactic Pharma LLC
567,580US$54.0m0%no data
7.8%
AstraZeneca PLC
522,667US$49.8m0%1.89%
5.16%
Saturn V Capital Management LP
345,626US$32.9m6.12%5.14%
4.83%
Deerfield Management Company, L.P.
323,745US$30.8m89.8%0.35%
4.73%
BlackRock, Inc.
316,567US$30.1m24.2%no data
4.62%
Adage Capital Management, L.P.
309,195US$29.4m-51.7%0.04%
4.03%
Artal Group S.A.
270,118US$25.7m27.2%0.39%
3.95%
ADAR1 Capital Management, LLC
264,278US$25.2m13%1.32%
3.38%
Polar Capital Holdings Plc
226,526US$21.6m114%0.05%
3.26%
Vanguard Capital Management, LLC
218,463US$20.8m0%no data
2.6%
Wellington Management Group LLP
174,342US$16.6m-22.9%no data
2.59%
Sio Capital Management, LLC
173,506US$16.5m0%1.98%
2.42%
Chandler Robinson
162,082US$15.4m5.73%no data
2.04%
Balyasny Asset Management L.P.
136,443US$13.0m328%0.03%
1.97%
TCG Crossover Management, LLC
132,103US$12.6m-6.91%0.24%
1.58%
Michael Brown
105,751US$10.1m124%no data
1.49%
Alyeska Investment Group, L.P.
100,000US$9.5m150%0.02%
1.49%
Geode Capital Management, LLC
99,918US$9.5m0.92%no data
1.4%
Diane Hendricks
93,750US$8.9m0%no data
1.35%
Vivo Capital, LLC
90,500US$8.6m0%0.67%
1.32%
State Street Global Advisors, Inc.
88,355US$8.4m5.2%no data
1.17%
BNY Asset Management
78,618US$7.5m21.2%no data
0.98%
Vestal Point Capital, LP
65,418US$6.2m0%0.15%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/08 22:25
End of Day Share Price 2026/07/08 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Monopar Therapeutics Inc. is covered by 17 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Brian Kemp DolliverBrookline Capital Markets
Suranjit MukherjeeBTIG